

Evoform Biosciences to Present at Aegis Virtual Conference on Wednesday, February 23, 2022

SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- Evoform Biosciences, Inc., (NASDAQ: EVFM) will present at the Aegis Virtual Conference as follows:

Date:	Wednesday, February 23, 2022
Time:	4:30 p.m. ET (1:30 p.m. PT)
Access Webcast:	https://evoform.investorroom.com/Aegis2022 or https://us02web.zoom.us/j/86168915443
Add to Calendar:	iCalendar (.ics) file

About Evoform Biosciences

Evoform Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evoform.com.

Phexxi® is a registered trademark of Evoform Biosciences, Inc.

Investor Relations Contact

Amy Raskopf
Evoform Biosciences, Inc.
araskopf@evoform.com
Mobile: (917) 673-5775

SOURCE Evoform Biosciences, Inc.
